Document:

gthp_ex10-61

  Exhibit 10.61

 

AMENDMENT
# 1 TO THE SECURITIES PURCHASE AGREEMENT AND SENIOR SECURED
CONVERTIBLE PROMISSORY NOTE DATED DECEMBER 17, 2019

 

THIS
AMENDMENT #1 (the “Amendment”) TO THE SECURITIES
PURCHASE AGREEMENT AND SENIOR SECURED CONVERTIBLE PROMISSORY NOTE
dated December 17, 2019, is made effective as of May 27, 2020 (the
“Effective Date”), by and between Guided Therapeutics,
Inc. a Delaware corporation (the “Company”), and Auctus
Fund, LLC, a Delaware limited liability company (the
“Holder”) (collectively the
“Partiers”).

 

BACKGROUND

 

A.

The Company and the
parties to the certain securities purchase agreement (the
“SPA”) and senior secured convertible promissory note
in the principal amount of $700,000.00 (the “Note”),
all dated December 17, 2019; and

B.

The Company and the
Holder desire to consummate a second tranche of $400,00.00 under
the Note (the “Second Tranche”), which principal amount
will be added to the Note on the Effective Date; and

C.

Accordingly, the
Parties desire to amend the SPA and Notes as set forth expressly
below.

 

NOW
THEREFORE, in consideration of the execution and delivery of the
Amendment and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties agree
as follows:

 

1.

The principal
balance of the Note shall be increased by $400,000.00 in the
Effective Date to reflect the addition of the Second Tranche to the
Note, which the Holder will fund on or around the date hereof as
specified in the disbursement authorization attached hereto as
Exhibit “A”.

2.

With respect to the
Company’s prepayment of the Second Tranche under Section 1.9
of the Note, the references to “Issue Date” throughout
Section 1.9 of the Note shall be amended to “the date that
the Holder Funded the purchase price for the second tranche of
$400,000.00 under this Note as specified in that certain amendment
#1 to the Purchase Agreement and this Note”.

3.

The following
sentence shall be added to Section 3 (q) of the SPA:

“With respect
to the consummation of the second tranche of $400,000.00 under the
Note as specified in that certain amendment #1 to this Agreement
and the Note dated May 27, 2020, the Company has taken no action
which would give rise to any claim by any person for brokerage
commissions, transaction fee or similar payments except with
respect to J.H.Darbie & Co., a registered broker-dealer (CRD#:
43520).”

 

4.

This Amendment
shall be deemed part of, but shall take precedence over and
superseded any provisions to the contrary contained in the SPA and
Note. Except as specifically modified hereby, all of the provisions
of the SPA and Note, which are not in conflict with the terms of
this Amendment, shall remain in full force and effect.

 

 

[Signature page to follow]

 

 

 

 

 

IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as
of the date first above written.

 

 

Guided
Therapeutics, Inc.

By:
/Gene S. Cartwright/

Name:
Gene S. Cartwright

Title:
CEO & President

 

 

 

Auctus
Fund, LLC

By:
/Lou Posner/

Name:
Lou Posner

Title:
Managig Directorgthp_ex10-62

  Exhibit 10.62

 

AMENDED FINDER'S FEE AGREEMENT

 

THIS
AMENDMENT TO THE AMENDED FINDER'S FEE AGREEMENT IS DATED JUNE 11,
2020 (the Effective Date")

BETWEEN:

 

Guided
Therapeutics Inc., a US registered public company incorporated in
the State of Delaware with a registered and records office at 5835
Peachtree Corners East, Suite B Norcross GA 30092.

("the
Company")

 

AND

 

Fieldhouse
Capital Management Inc., a British Columbia, Alberta, Saskatchewan,
Manitoba, and Ontario Registered Exempt Market dealer with a
registered and records office at 230 -11 Mainland St., Vancouver,
BC V6B 5L1..

("the
Finder")

 

The
Company and the Finder hereby amend the Finder's Agreement
previously entered into by the parties
on or about April 10, 2019 in the following regards:

 

WHEREAS:

 

A.
The parties entered into an Amended Finder's Fee Agreement dated on
or about May 22, 2020 in regards to a completed Series D Financing
in December 2019 and the Company is in the process of closing a
2020 Series E Preferred Share Financing. which the parties agree is
to be further amended.

 

B.
Unchanged.

 

C.
Unchanged.

 

1.
FINDER SERVICES AND FEES 1.1-1.3 Unchanged

 

1.4
Finder's Fees. The Company agrees to provide the following
consideration to the Finder:

 

(a)
As an approved Finder, payment in cash consisting of:

 

i)
Five Percent (5%) of the gross proceeds raised ("GPR") from all
accepted subscription agreements for the 2020 Series E Preferred
Share financing ("2020 Financing") from investors introduced to the
Company by the Finder (the "Fee").

 

ii)
Two percent (2%) from the 2019 Series D financing only (which
amounts to $15,260 based on gross proceeds of
$763,000).

 

iii)
Based on the GPR by Finder, there shall be a payment to Finder
based on the percentages and caps shown in the table below from the
exercise of any warrants for the period of 3 years after the 2020
Financing that have been or will be issued in connection with this
and prior financings and debt settlements ("warrant exercise
commissions"); provided however that warrant exercise commissions
shall expire three (3) years from the close of the 2020
Financing.

 

 

 

 

 

 

b)
Deleted

 

 

1.5.
Fee Payment Terms: The Fee shall be paid within 5 business days
after all funds have been received by the Company in the 2020
Financing.

 

1.6-1.7:
Unchanged.

 

2.
TERM OF AGREEMENT

 

2.1.
The term of this agreement shall be three (3) years from the close
of the 2020 Series E Financing.

 

3-9.
Unchanged. IN WITNESS WHEREOF this Amendment has been executed by
the parties hereto on the Effective Date.

 

Guided
Therapeutics, Inc.

By:
/Gene Cartwright/

Title:
CEO & President

 

 

 

Fieldhouse
Capital Management, Inc

By:
/Douglas Sereda/

Title:
Chief Executive Officer (CEO) Directorgthp_ex10-63

 

Exhibit 10.63

 

EXCHANGE
AGREEMENT

 

 

 

This
EXCHANGE AGREEMENT (this "Agreement") is made and entered into
effective as of the 9th day of July, 2020
by and between GUIDED THERAPEUTICS, INC., a Delaware corporation
(the "Company") and the undersigned creditor of the Company (the
"Creditor").

 

 

W I T N E S S E T H :

 

WHEREAS, the
Creditor is the payee of certain obligations owed to the Creditor
by the Company as set forth on Exhibit A hereto (the
"Obligations");

 

NOW,
THEREFORE, in consideration of the mutual covenants herein
contained, and intending to be legally bound hereby, the parties
hereto, being duly sworn, do covenant, agree and certify as
follows:

 

1. Recitals. The
parties hereto acknowledge and agree that the foregoing recitals
are true and accurate and constitute part of this Agreement to the
same extent as if contained in the body hereof.

 

2.           
Exchange and
Satisfaction. The Obligations are hereby
surrendered by the Creditor and exchanged for the Note and other
considerations according to the following terms and
conditions.

 

a.

The Creditor is or
has been a manager or consultant of the Company and
both parties wish to continue their relationship under
mutually agreeable terms.

 

b.

In lieu of agreeing
to dismiss approximately half of what he is currently owed
by the Company, the Creditor agrees to accept:

 

(i)

Cash payments of
$20,000.00 (Twenty Thousand Dollars and Zero Cents). The cash
payments shall be made as follows:

●

$10,000 upon the
signing of this Agreement

●

$5,000 within 30
days of the signing of this Agreement

●

$5,000 within 60
days of the signing of this Agreement

(ii)

Cash payments over
time in the amount of $90,000.00 (Ninety Thousand Dollars and Zero
Cents) in the form of an unsecured note with the Company to be
executed within 30 days of the closing of a new financing or new
financings totaling at least $3 million. The note shall have a term
of 18 months, carry a six percent (6%) annual interest rate and be
paid at a rate of $5,000.00 (Five Thousand Dollars and Zero Cents)
per month starting 30 days after the closing of the new financing
or new financings totaling at least $3 million.

(iii)

66,000 stock
options that vest at a rate of 1/18th or 3,667 per month.
Should two consecutive payments under term 2.b (i) or (ii) be
missed, then any remaining stock options will be canceled and
instead cash payments of $66,000.00 (Sixty-six Thousand Dollars and
Zero Cents) will be added to the total amount owed and payable at a
rate of $6,000.00 (Six Thousand Dollars and Zero Cents) per month
starting in month 19 after the closing of a financing of a least $2
million.

(iv)

The total amount of
forgiveness by Creditor of approximately $110,000.00 shall be
prorated according to the amount of funds paid to Creditor. For
example, once the first $20,000.00 of payment is made, then
Creditor has forgiven $20,000.00. Once all $110,000.00 has been
paid and equity described in Section 2(b)(iii) awarded to Creditor,
then terms and conditions of this Agreement shall have been deemed
fully satisfied.

 

3.           Successors
and Assigns. This Agreement is
binding upon, and shall inure to the benefit of, the parties hereto
and their respective successors and assigns.

 

4.           Counterparts. This
Agreement may be executed in multiple counterparts, each of which
shall be deemed an original and all of which, when taken together,
shall constitute one and the same instrument.

 

 

 

IN
WITNESS WHEREOF, the parties hereto have affixed their hands and
seals by signing this Agreement as of the day and year first above
written.

 

 

 

[Signatures on
Following Page]

 

 

 

 

 

 

 

 

Company:

 

GUIDED
THERAPEUTICS, INC.

 

 

By:  /Gene S.
Cartwright/

Name:
Gene Cartwright

Title:
President and CEO

 

 

 

 

Creditor:

 

 

By:
/William Wells/

Name:
William Wells

 

 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]